← Eichor
Study identifier: NCT04840264 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction

Condition: Metastatic Gastric Adenocarcinoma · Metastatic Gastroesophageal Junction Adenocarcinoma · Peritoneal Carcinomatosis  ·  Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

PhasePhase 2
Planned participants79
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This is a multi-center, non-randomized, 3-cohort, phase II trial, evaluating a triplet combination of docetaxel, oxaliplatin and fluorouracil for gastric cancer with peritoneal carcinomatosis and inoperable malignant bowel obstruction.

This description comes directly from the study's public registry record.

Talk to the study team

Jian Xiao, MD  ·  86-20-81884713  ·  xiao_jian@139.com

Always discuss trial participation with your own doctor first.

Locations (1)

Guangdong Provincial People's HospitalGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04840264